세계의 인유두종 바이러스 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Human Papillomavirus Vaccines Market was valued at USD 5.4 billion in 2024 and is estimated to grow at a CAGR of 10.1% to reach USD 14.1 billion by 2034. This expansion is largely driven by the rising incidence of HPV infections, which contribute to cervical, anal, oropharyngeal, and other anogenital cancers worldwide. Increasing awareness about HPV-related cancers and the importance of vaccination programs is further propelling market growth. The rising burden of HPV-associated diseases in both developed and developing countries, coupled with public health efforts to promote widespread immunization and cervical cancer treatment, is a significant growth factor.

Additionally, the increasing prevalence of HPV infections in men and the adoption of gender-neutral vaccination strategies are broadening the target population and boosting demand for HPV vaccines. Advances in vaccine technology, such as recombinant DNA techniques and virus-like particle platforms, are leading to the development of next-generation vaccines that offer broader protection and longer-lasting immunity. Moreover, emerging manufacturers are focusing on local production to provide affordable vaccines and meet growing demand in developing regions. The HPV vaccines market is centered around the development, manufacture, and distribution of vaccines that prevent HPV infections, primarily delivered through immunization programs targeting adolescents and young adults.

The market is segmented by type into bivalent, quadrivalent, and nonavalent vaccines. The nonavalent vaccine segment held the largest share in 2024, valued at USD 3.9 billion. Increased awareness of HPV-related cancers has led healthcare providers and governments to prioritize vaccines targeting the most oncogenic HPV strains. The nonavalent vaccine offers protection against nine high-risk HPV types (16, 18, 31, 33, 45, 52, and 58), providing a wider coverage that addresses critical public health needs. Government immunization initiatives have played a pivotal role in the increased adoption of nonavalent vaccines.

The female segment dominated the market in 2024 and is anticipated to grow at a CAGR of 9.9%. Since HPV infection is closely linked to cervical cancer, vaccination programs primarily target females to reduce the incidence of HPV-related diseases. Public health policies and international recommendations have emphasized female immunization, which has significantly boosted demand. Enhanced awareness and education around women's health, supported by public campaigns and NGOs, have increased vaccine uptake among girls and young women. The growing involvement of parents and caregivers has also reinforced the dominance of this segment.

U.S. Human Papillomavirus Vaccines Market was valued at USD 2.2 billion in 2024. The rising number of HPV cases in the country drives the need for preventive vaccines. Public health initiatives, a high disease burden, robust healthcare infrastructure, and increased government investments in preventive healthcare are key factors fueling market growth. Gender-neutral vaccination policies and school-based immunization programs continue to push demand within the U.S.

Key players in the Human Papillomavirus Vaccines Market include Inovio Pharmaceuticals, Serum Institute of India, Recbio, GlaxoSmithKline, Merck, Walvax Biotechnology, Genexine, Sanofi Pasteur, Xiamen Innovax, and Yuxi Zerun Biotech. Companies in the HPV vaccines market focus on innovation by investing in the development of next-generation vaccines that provide broader and longer-lasting protection. Strategic partnerships with research institutions and biotechnology firms enable accelerated product development and regulatory approvals.

Expanding manufacturing capacities and enhancing distribution networks help meet rising global demand, especially in developing regions. Firms are also prioritizing affordability and accessibility by collaborating with local manufacturers to reduce costs. Additionally, targeted awareness campaigns and advocacy efforts promote vaccine adoption, supporting market growth and strengthening their presence worldwide.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumption and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Type
  • 2.2.3 Indication
  • 2.2.4 Gender
  • 2.2.5 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of HPV-related cancers
    • 3.2.1.2 Increasing shift toward gender-neutral vaccination policies
    • 3.2.1.3 Growing awareness and education campaigns
    • 3.2.1.4 Technological advancements in vaccine development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced vaccines
    • 3.2.2.2 Lack of infrastructure for mass immunization
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expanding immunization programs in developing countries
    • 3.2.3.2 Public-private partnerships in vaccine distribution
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Bivalent
• 5.3 Quadrivalent
• 5.4 Nonavalent

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Cervical cancer
• 6.3 Vaginal and vulvar cancer
• 6.4 Anal cancer
• 6.5 Oropharyngeal cancer
• 6.6 Other indications

Chapter 7 Market Estimates and Forecast, By Gender, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Female
• 7.3 Male

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Genexine
• 10.2 GlaxoSmithKline
• 10.3 Inovio Pharmaceuticals
• 10.4 Merck
• 10.5 Recbio
• 10.6 Sanofi Pasteur
• 10.7 Serum Institute of India
• 10.8 Walvax Biotechnology
• 10.9 Xiamen Innovax
• 10.10 Yuxi Zerun Biotech